EyePoint Halves Workforce and Ends Pivotal Wet AMD Trials After Second Phase 3 Failure
Start here
EyePoint's duravyu has failed the Phase 3 Lucia trial in wet AMD, missing the non-inferiority primary endpoint and marking the program's second Phase 3 failure after the Lugano trial. In response, the company will cut about 53% of its workforce, roughly 113 people, and end its pivotal wet AMD trials early, taking an estimated $9 million in layoff-related charges. The company held $180.5 million in cash and marketable securities as of June 30. EyePoint is now shifting its focus to two Phase 3 readouts for duravyu in diabetic macular edema, which remain pending.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- BioSpacePickEyePoint will halve workforce, end pivotal wet AMD trials early following second fail
EyePoint announced Monday that duravyu failed to meet the non-inferiority primary endpoint in the Phase 3 Lucia trial in wet AMD, the second Phase 3 failure after the Lugano trial. The company will cut about 53% of its workforce (about 113 people) and end its pivotal wet AMD trials early, shifting to two Phase 3 readouts for duravyu in diabetic macular edema (DME). The announcement disclosed cash and marketable securities investments of $180.5 million as of June 30 and workforce-reduction charges of about $9 million.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 20 01:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.